USPTO Patent Applications - Biotech (C12N)

Stabilized Enveloped Viruses by Spray-Drying and Lyophilization

The USPTO published patent application US20260091106A1 on April 2, 2026, disclosing compositions and methods for making thermostable enveloped viruses using spray-drying and lyophilization techniques. The inventions aim to reduce degradation, preserve virus activity and titer, and prolong storage stability for transport and later use. Application 19348562 was filed October 2, 2025 by inventors Coleman, Randolph, Schwartz, and Garcea.

NADC34-like PRRSV-2 Vaccine Plasmid and Mutant Strain rBJ-VVL

Yangzhou University filed a patent application (US20260091100A1) with the USPTO for an rBJ-VVL plasmid and mutant NADC34-like PRRSV-2 strain with tropism for Marc-145 cells. The modified strain incorporates precise mutations at amino acid positions 91/97/98 of GP2a, enabling viral propagation and plaque formation in Marc-145 cells. This represents the first disclosed NADC34-like PRRSV-2-specific vaccine candidate derived from a Marc-145-adapted modified strain.

Culture and Kit-of-Part of Bacterial Strains

USPTO published patent application US20260090557A1 for bacterial cheese culture strains and kits for manufacturing pasta-filata cheese. The application covers galactose-positive Streptococcus thermophilus strains and methods for producing stretched curd cheese using defined culture combinations. Filing date was December 10, 2025.

Cancer Treatment Patent - Two-Part Treatment Regime

The USPTO published patent application US20260091097A1 for a two-part cancer treatment regime involving antigen-specific T cell therapy followed by inflammation-inducing treatment. The application, filed on April 18, 2025, covers methods of treating cancer using sequential administration of treatments to generate tumor-specific immune responses. Inventors include Geoffrey Martin Lynn, Christopher Martin O'Brien Garliss, and others.

Cardiac Xenograft Rejection Measurement Methods

The USPTO published patent application US20260091096A1 disclosing methods for measuring cardiac xenograft immune rejection progress. The application covers transgenic pig preparations with reduced glycan antigens (Sda/SDa-like and α-Gal) and recipient immunological response modifications targeting CD46, CD59, CD9, PROCR, and ANXA2. Inventors are Guerard W. Byrne and Christopher G.A. McGregor, with priority date September 15, 2025.

Urate Oxidase-Albumin Conjugate Patent Application

USPTO published patent application US20260091090A1 for a urate oxidase-albumin conjugate invented by seven researchers. The conjugate uses three or more albumins conjugated through a linker to a urate oxidase variant, improving half-life and reducing immunogenicity. The invention addresses prevention and treatment of diseases caused by uric acid, such as gout and hyperuricemia.

Pyocyanin Demethylases Engineered for Bacteria

The USPTO published patent application US20260091089A1 for engineered pyocyanin demethylases with amino acid replacements at positions A53, 173, A87, T91, M99, A129, and K141 of PodA. The application covers compositions, methods, and systems for interfering with bacterial viability through pyocyanin demethylase activity, including synergistic combinations with antibiotics. Application 19312182 was filed August 27, 2025.

Lipid Nanoparticles Comprising Nucleic Acids Encoding Therapeutic Genes and Uses in Medical Methods

The USPTO published patent application US20260090997A1 by Sorscher et al. disclosing lipid nanoparticle compositions comprising nucleic acids encoding therapeutic genes for treating cancer. The application was filed September 20, 2023, and published April 2, 2026. Inventors include researchers from Emory University and Georgia Institute of Technology working on targeted gene therapy delivery systems.

Lipid Nanoparticle mRNA Vaccines

USPTO published patent application US20260090989A1 by CureVac SE for lipid nanoparticle mRNA vaccine compositions. The application covers cationic lipids according to formulas (I)-(III), PEG lipids per formula (IV), and mRNA encoding antigens for influenza and rabies vaccination. The filing (Application No. 19409837) lists 14 inventors including Patrick Baumhof, Mariola Fotin-Mleczek, and Michael J. Hope.

Engineered Polynucleotide for Cancer Treatment

The USPTO has published a patent application detailing an engineered polynucleotide designed to treat cancer by regulating gene expression. The application, filed on July 17, 2025, describes compositions and methods involving polynucleotides that interact with pre-mRNA and spliceosomes.

Patent Application: Cancer Treatment with Stat3 Decoy

The USPTO has published a new patent application (US20260085318A1) detailing methods for treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor. The application was filed on September 20, 2023, by inventors Daniel E. Johnson and Jennifer R. Grandis.

siRNA for AGT gene expression inhibition in hypertension treatment

The USPTO has published a new patent application (US20260085317A1) detailing modified oligonucleotide sequences designed as siRNAs to inhibit angiotensinogen (AGT) gene expression. The application suggests these siRNAs may be used in the development of treatments for hypertension and related diseases.

HMBOX1 Inhibitor for Muscle Atrophy Treatment

The USPTO has published a patent application (US20260085316A1) from Shanghai University detailing the use of a homeobox containing 1 (HMBOX1) inhibitor for the prevention and treatment of muscle atrophy. The application outlines findings from cellular and animal studies supporting the therapeutic potential of inhibiting HMBOX1 expression.

Conjugated Oligonucleotide Compounds for Therapeutic Use

The USPTO has published a new patent application (US20260085314A1) for conjugated oligonucleotide compounds, methods of making them, and their therapeutic uses. The application was filed on May 16, 2025, by inventors Ahmad Ali Mortazavi, Viviana Mannella, and Muthusamy Jayaraman.

USPTO Patent Application for Modulating SMN2 RNA and Protein

The USPTO has published a patent application (US20260085313A1) detailing compounds, methods, and pharmaceutical compositions for modulating SMN2 RNA and protein. This application, filed on May 2, 2025, aims to ameliorate symptoms of neurodegenerative disorders.

Composition for Regulating Interfering Ribonucleic Acid Production

The USPTO has published a new patent application (US20260085312A1) detailing compositions and methods for regulating interfering ribonucleic acid (miRNA) production. The application describes techniques to decrease the bioavailability of target biomolecules by degrading or inactivating their corresponding messenger RNA (mRNA).

Patent Application: Compositions and Methods for Reducing RNA Levels

The USPTO has published a new patent application (US20260085311A1) detailing compositions and methods for reducing RNA levels and treating diseases caused by toxic gain-of-function proteins. The application was filed on June 20, 2023.

Patent Application for Antisense Oligonucleotide Targeting TDP-43 mRNA

The USPTO has published a patent application (US20260085310A1) filed by NIPPON SHINYAKU CO., LTD. The application describes an antisense oligonucleotide targeting TDP-43 mRNA or pre-mRNA for potential therapeutic use. The filing date was May 26, 2023.

Patent Application for cDNA Synthesis and Transcriptome Profiling

The USPTO has published a patent application (US20260085309A1) for compositions and methods related to cDNA synthesis and transcriptome profiling. The application details optimized template switching oligonucleotides designed to improve reverse transcription specificity and prevent concatemer formation. This is a new patent application filing, not a final rule or guidance.

Patent Application for Propagator Cells and Phage Propagation Methods

The USPTO has published a new patent application (US20260085296A1) detailing propagator cells and methods for propagating phage, particularly for delivering CRISPR-Cas components via probiotic organisms. The application was filed on December 4, 2025.

Method for Trans-Differentiating Non-Neuronal Cells into Neurons

The USPTO has published a patent application (US20260085284A1) from SHANGHAI GENEMAGIC BIOSCIENCES CO., LTD. for a method of trans-differentiating non-neuronal cells into neurons using specific regulators. The application was filed on August 30, 2023.

Patent Application: Compositions for Treating CHD2 Haploinsufficiency

The USPTO has published a patent application (US20260085319A1) for compositions and methods to treat CHD2 haploinsufficiency. The application details a method of increasing Chromodomain Helicase DNA Binding Protein 2 (CHD2) in neuronal cells using a nucleic acid agent.

Methods for Generating cDNA Library from RNA

The USPTO has published a patent application (US20260085308A1) detailing methods for the fast and efficient generation of cDNA libraries from RNA. The application, filed on September 11, 2023, by inventors Keith Brown, Steven Head, and Phillip Ordoukhanian, describes a method adaptable for automation.

Genome-wide insulator screening system disclosed

The USPTO has published a patent application detailing a genome-wide insulator screening system. The system, comprising specific MAI-seq vectors, is designed for high-sensitivity screening of genomic insulators and is applicable to any species.

Patent Application for Nucleic Acid Library Preparation

The USPTO has published a new patent application, US20260085306A1, detailing ligation-free methods for preparing nucleic acid libraries for high-throughput sequencing. The application was filed on January 16, 2024, and published on March 26, 2026.

Methods for adding polymers to ribonucleic acids

The USPTO has published a patent application detailing methods for adding polymers of non-canonical nucleotides to the 3' end of ribonucleic acids (RNA). The application, filed by inventors from institutions including the University of California, describes techniques that may be used for RNA analysis and identification. This publication represents a new patent application and does not impose immediate regulatory obligations.

Novel cell wall hydrolases target Cutibacterium acnes conditions

The USPTO has published a patent application (US20260085303A1) detailing novel cell wall hydrolases designed to target Cutibacterium acnes. The application describes compositions and uses for treating conditions associated with this bacterium.

Patent Application: Plant Pest Control using Cas12a2 Protein

The USPTO has published a patent application (US20260085302A1) from Confluence Genetics, LLC, detailing methods and compositions for controlling plant pests using Cas12a2 protein and guide polynucleotides. The application describes targeting specific DNA or RNA sequences within plant pests for elimination.

Method to enhance CAR-T cell efficacy using NOS inhibitor

The USPTO has published a patent application (US20260083844A1) detailing a method to enhance CAR-T cell efficacy by downregulating nitric oxide synthase (NOS). This application describes a potential therapeutic approach for treating B cell malignancies that are resistant to current CAR-T cell treatments.

Patent Application: Genome Modification Compositions and Methods

The USPTO has published a new patent application (US20260085301A1) from Confluence Genetics, LLC, detailing compositions and methods for targeting and eliminating cells with pre-determined DNA sequences using Cas12a2 protein. The application was filed on September 19, 2025.

Patent Application for Engineered Pyrococcus Enzymes

The USPTO has published patent application US20260085299A1 for engineered Pyrococcus enzymes designed for improved nucleotide analogue incorporation in DNA sequencing. The application was filed on May 27, 2025.

Method for Efficient Biosynthesis of Rebaudioside M2 Using Glycosyltransferase

The USPTO has published a patent application detailing a method for the efficient biosynthesis of rebaudioside M2 using glycosyltransferase. The assignee, GUILIN LAYN NATURAL INGREDIENTS CORP., claims this method provides an environmentally friendly way to produce rebaudioside M2 with no by-products, potentially reducing production costs.

Bacterial Superoxide Dismutases Patent Application

The USPTO has published a patent application (US20260085297A1) filed by Novozymes A/S for bacterial superoxide dismutases. The application, filed on August 29, 2025, describes polypeptides useful in animal feed additives for improving growth, performance, and health.

Patent Application for AAV Purification Using Anion Exchange Chromatography

The USPTO has published a patent application (US20260085295A1) detailing methods for purifying adeno-associated viruses (AAV) using anion exchange chromatography. The application, filed on September 23, 2025, by inventors Garima Thakur, Sheldon Robert Mink, and Andrew David Tustian, focuses on enhancing purification efficiency and concentration.

Process for Producing Purified Rhabdovirus from Cell Culture

The USPTO has published a patent application detailing a process for producing a purified rhabdovirus from cell culture, specifically oncolytic rhabdoviruses like vesicular stomatitis virus. The application, filed on August 21, 2025, outlines methods for both upstream and downstream processing.

USPTO Patent Application for Body Fluid Sample Transport Solution

The USPTO has published a new patent application (US20260085293A1) detailing a solution and method for transporting or storing body fluid samples. The application, filed on March 27, 2024, by inventors Mitsumi NISHI, Noriko MIYAUCHI, and Rieko SHIMAMURA, describes a solution containing specific active ingredients for sample preservation.

Minimal Essential Media for Human Induced Pluripotent Stem Cells

The USPTO has published a patent application (US20260085292A1) detailing minimal essential media for culturing human induced pluripotent stem cells (iPSCs). The application was filed on September 11, 2023, by inventor Paul Wesley Burridge.

Patent Application: Diabetes Prevention/Treatment by Myeloid Suppressor Cell Activity

The USPTO has published a new patent application (US20260085291A1) from CREATIVE MEDICAL TECHNOLOGIES, INC. The application details methods and compositions for preventing or treating Type 1 diabetes by augmenting myeloid suppressor cell activity, potentially involving conditioned immune cells or exogenous suppressor cells.

Patent Application for Feeder Cells and Cell Sheet Production

The USPTO has published a new patent application (US20260085290A1) filed by DAI NIPPON PRINTING CO., LTD. The application details a method for producing feeder cells and cell sheets, derived from pluripotent stem cells, intended for maintaining or proliferating difficult-to-culture cells. This is a standard publication of a patent application.

Use of G007-LK for Osteogenic Differentiation and Bone Regeneration

The USPTO has published patent application US20260085289A1, detailing the use of a compound known as G007-LK. The application, filed by the Hospital of Stomatology, Guangzhou Medical University, describes G007-LK's potential to promote osteogenic differentiation of dental stem cells and aid in bone tissue regeneration.

CRISPR/Cas13a Kit for Rapid ALV-J Detection

The USPTO has published a patent application for a CRISPR/Cas13a kit designed for the rapid detection of avian leukosis virus subgroup J (ALV-J). This application details a method combining CRISPR/Cas13a with recombinase aided amplification for improved sensitivity and specificity in detecting ALV-J.

Patent Application: Conditioned Media, Cultured Cells Production

The USPTO has published a new patent application, US20260083818A1, detailing a system and method for the production, formulation, and use of conditioned media and cultured cells. The application was filed on May 7, 2025, and describes techniques for culturing various cell types, including animal and plant cells, together.

mRNA Vaccine and Immune Modulator Combination Patent Application

The USPTO has published a patent application (US20260083837A1) for a combination comprising mRNA molecules for vaccines or therapeutic proteins, along with immune-modulating mRNA. The application details combinations for improved or reduced immunogenicity to increase efficacy, and relates to host cells, pharmaceutical compositions, vaccines, and kits for medical use.

Patent Application: Alpha-Glucosidase Compositions for Pompe Disease Treatment

The USPTO has published a new patent application (US20260083829A1) from Amicus Therapeutics, Inc. The application details compositions comprising high concentrations of acid alpha-glucosidase and active site-specific chaperones for treating Pompe disease. It also covers methods for increasing enzyme stability.

Patent Application for Treating DNAse1 Deficiency Diseases

The USPTO has published a new patent application (US20260083828A1) detailing compositions and methods for treating diseases associated with DNAse1 and/or DNAse1L3 deficiency. The application was filed on September 11, 2025, by inventors Demetrios Braddock, Paul Stabach, and Ethan Lester.

Patent Application for Engineered Bacteriophage Transducing Particles Production

The USPTO has published a new patent application (US20260083787A1) from TROBIX BIO LTD. for systems and methods for producing engineered bacteriophage transducing particles. The application details novel approaches for manipulating bacterial populations using these particles and associated regulatory elements.

Antimicrobial use of Micrococcus porci against Staphylococcus species

The USPTO has published a patent application detailing the selective antimicrobial use of Micrococcus porci against harmful Staphylococcus species. The application describes compositions comprising Micrococcus porci for use in cosmetics, quasi-drugs, external skin preparations, or medicines.

Patent Application: Complex for Cartilage Differentiation

The USPTO has published a new patent application (US20260083780A1) detailing a complex for promoting cartilage differentiation. The application describes a method for fabricating cartilage and a pharmaceutical composition for treating arthropathy, filed on June 2, 2025.

Edible Aerial Mycelium Patent Application

The USPTO has published a patent application (US20260083160A1) filed on November 5, 2023, for edible aerial mycelium, methods of preparation, and food products containing them. The application includes hybrid food products with aerial mycelium and meat.

Coffee Fermentation Using Pichia Kluyveri and Lactiplantibacillus Plantarum

The USPTO has published a patent application (US20260083149A1) from CHR. HANSEN A/S detailing a method for coffee fermentation using specific yeast and bacteria strains. The application focuses on improving coffee bean and beverage production through controlled fermentation processes.